Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based. Read more…
Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards Greater Understanding
26 June 2024
Our literature review suggests that there are more than 100 inequalities impacting on people living with dementia and their carers across multiple characteristics, circumstances, and in various parts of the health and care system. However, the current low availability and quality of data is a major barrier to accurately measuring these inequalities. With the expectation that 1 in 2 people will be affected by dementia during their lifetime, there is a pressing need for further research to inform future policy, research, and service interventions.
A Framework for Value-aligned Pricing of Combination Therapies
25 June 2024
Combination therapies can provide effective treatment options and improve patient outcomes. However, there are significant barriers to patient access to combination therapies, including the prevailing pricing models used in Europe.
Around the World in HTAs: United States – Making HTA Great Again
11 June 2024
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Chris Sampson and Dan Ollendorf take us to the United States.
How Have HTA Agencies Evolved Their Methods Over Time?
29 April 2024
The many changes in Health Technology Assessment (HTA) methods and processes over time, are a challenge to navigate let alone stay abreast of. This report explores the breadth of variation in past and current positioning of HTA agencies in 14 countries, on five key methodological topics: discount rates, modifiers, patient involvement, real-world evidence (RWE), and surrogate endpoints.
Adult vaccination programmes deliver socio-economic benefits up to 19 times initial investment, according to new report
18 April 2024
Our new report examines the promise of prevention in healthcare and provides six key recommendations that could usher in a new era of optimised prevention.
Socio-Economic Value of Adult Immunisation Programmes
18 April 2024
Adult vaccines can return up to 19 times their initial investment to society, when their significant benefits beyond the healthcare system are monetised.
Around The World in HTAs: Türkiye – The bumpy road toward transformation
31 January 2024
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Prof Hasan Huseyin Yildirim, Dilek Sernur Eminoğulları, Dr Tuba Saygın Avşar, and Patricia Cubi-Molla take us to Türkiye.
Individual, Health System, and Societal Impacts of Anti-seizure Medicine Use During Pregnancy
23 January 2024
Explore the implications of in utero exposure to anti-seizure medications (ASMs), the heightened risks of developmental problems and physical disabilities. The economic impact associated with conditions like epilepsy, stressing the urgent need for detailed risk profiles and data collection to guide interventions and reduce the societal costs linked to ASM use during pregnancy.
Could Plant-based Diets Transform Health Care Spending?
8 January 2024
In a bid to reduce health care budgets, policymakers and healthcare professionals are increasingly looking to prevention strategies.